https://scholars.lib.ntu.edu.tw/handle/123456789/551195
標題: | Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma | 作者: | ANN-LII CHENG Ying-Chun Shen Zhu A.X. |
公開日期: | 2012 | 卷: | 81 | 期: | 5��6�� | 起(迄)頁: | 372-380 | 來源出版物: | Oncology | 摘要: | Hepatocellular carcinoma (HCC) is the primary type of liver cancer, and both the age-adjusted incidence and mortality of HCC have steadily increased in recent years. Advanced HCC is associated with a very poor survival rate. Despite accumulating data regarding the risk factors for HCC, the mechanisms that contribute to HCC tumorigenesis remain poorly understood. Signaling through the fibroblast growth factor (FGF) family is involved in fibrosis and its progression to cirrhosis of the liver, which is a risk factor for the development of HCC. Furthermore, several alterations in FGF/FGF receptor (FGFR) signaling correlate with the outcomes of HCC patients, suggesting that signaling through this family of proteins contributes to the development or progression of HCC tumors. Currently, there are no established systemic treatments for patients with advanced HCC in whom sorafenib treatment has failed or who were unable to tolerate it. Recently, several multikinase inhibitors that target FGFRs have demonstrated some early evidence of antitumor activity in phase I/II trials. Therefore, this review discusses the molecular implications of FGFR-mediated signaling in HCC and summarizes the clinical evidence for novel FGFR-targeted therapies for HCC currently being studied in clinical trials. Copyright ? 2012 S. Karger AG, Basel. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84856065348&doi=10.1159%2f000335472&partnerID=40&md5=3fd2fb84e0965d920e2e3dd9d8d23311 https://scholars.lib.ntu.edu.tw/handle/123456789/551195 |
ISSN: | 0030-2414 | DOI: | 10.1159/000335472 | SDG/關鍵字: | brivanib; dovitinib; fibroblast growth factor 17; fibroblast growth factor 18; fibroblast growth factor 2; fibroblast growth factor 22; fibroblast growth factor 4; fibroblast growth factor 5; fibroblast growth factor 8; fibroblast growth factor 9; fibroblast growth factor receptor; fibroblast growth factor receptor 2; fibroblast growth factor receptor 3; fibroblast growth factor receptor 4; nintedanib; rabeprazole; sorafenib; unclassified drug; cell function; human; liver carcinogenesis; liver cell carcinoma; liver cirrhosis; liver fibrosis; molecularly targeted therapy; nonhuman; outcome assessment; priority journal; review; signal transduction; Animals; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Clinical Trials as Topic; Humans; Liver Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Receptors, Fibroblast Growth Factor; Signal Transduction |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。